Jean MacFadyen - Concepedia

Author

Jean MacFadyen

Brigham and Women's Hospital

Also Known As

J MacFadyen, J. MacFadyen, J.G. MacFadyen, Jean G MacFadyen, Jean G. MacFadyen, Jean MacFadyen, MacFadyen, Jean

Publications

36K

Citations

H-Index

Concepts

All Affiliations

Brigham and Women's Hospital Harvard University Universität Ulm Universidade Federal de São Paulo University of Amsterdam

About

Jean MacFadyen is an author at Brigham and Women's Hospital specializing in medicine, cardiovascular disease, and public health.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	20	23	11.2K
2	Public Health	13	13	7.8K
3	Health Sciences	2	2	794
4	Allergy	1	1	1.3K
5	Applied Physiology	1	1	262

Jean MacFadyen

Publications

33.7K

Citations

H-Index

Page 1

	Year	Citations
Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease Paul M. Ridker, Tom Thurén, Jean MacFadyen, New England Journal of Medicine	2017	8.7K
Rosuvastatin to Prevent Vascular Events in Men and Women with Elevated C-Reactive Protein Paul M. Ridker, Eleanor Danielson, Francisco Antônio Helfenstein Fonseca, New England Journal of Medicine	2008	6.5K
Rosuvastatin to Prevent Vascular Events in Men and Women With Elevated C-Reactive Protein Paul M. Ridker, Eleanor Danielson, Francisco Antônio Helfenstein Fonseca, Obstetrical & Gynecological Survey Vascular DiseaseElevated C-reactive ProteinUnstable AnginaHyperlipidemiaPharmacotherapy	2009	3.7K
Effect of interleukin-1β inhibition with canakinumab on incident lung cancer in patients with atherosclerosis: exploratory results from a randomised, double-blind, placebo-controlled trial Paul M. Ridker, Jean MacFadyen, Tom Thurén, The Lancet InflammationAllergyLung InflammationMedicineMetronomic Therapy	2017	1.3K
Low-Dose Methotrexate for the Prevention of Atherosclerotic Events Paul M. Ridker, Brendan M. Everett, Aruna D. Pradhan, New England Journal of Medicine	2018	1.2K
Reduction in C-reactive protein and LDL cholesterol and cardiovascular event rates after initiation of rosuvastatin: a prospective study of the JUPITER trial Paul M. Ridker, Eleanor Danielson, Francisco Antônio Helfenstein Fonseca, The Lancet Jupiter TrialCardiovascular DiseaseHyperlipidemiaLdl CholesterolDyslipidemia	2009	1K
Relationship of C-reactive protein reduction to cardiovascular event reduction following treatment with canakinumab: a secondary analysis from the CANTOS randomised controlled trial Paul M. Ridker, Jean MacFadyen, Peter Libby, The Lancet Cardiovascular ToxicityC-reactive Protein ReductionCardiovascular DiseaseCardiovascular PharmacologyEvent Reduction	2017	847
Cardiovascular benefits and diabetes risks of statin therapy in primary prevention: an analysis from the JUPITER trial Paul M. Ridker, Aruna D. Pradhan, Jean MacFadyen, The Lancet Metabolic SyndromePrimary PreventionJupiter TrialCardiovascular EpidemiologyCardiovascular Disease	2012	795
A Randomized Trial of Rosuvastatin in the Prevention of Venous Thromboembolism Robert J. Glynn, Eleanor Danielson, Francisco Antônio Helfenstein Fonseca, New England Journal of Medicine	2009	741
Triglyceride Lowering with Pemafibrate to Reduce Cardiovascular Risk Aruna D. Pradhan, Robert J. Glynn, Jean‐Charles Fruchart, New England Journal of Medicine	2022	638

Page 1